IDEAYA Biosciences (IDYA) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 4 Phase 2[2], 6 Phase 1[3].
Trial NCT07015190[5] evaluates Darovasertib in Uveal Melanoma with a target enrollment of 520 participants. Trial NCT05987332[6] evaluates IDE196 in Metastatic Uveal Melanoma with a target enrollment of 420 participants.
No Form 4 insider filings for IDYA were recorded at the SEC in the past 30 days[7].